NCT07213076Completed
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
A Retrospective Study of Treatment Patterns and Clinical Outcomes in Australian EGFR Mutant Advanced and Metastatic Non-Small Cell Lung Cancer NSCLC Patients: First-line and Second-line Osimertinib Usage
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line osimertinib.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 350 (actual)
- First submitted
- 1 Oct 2025
- Start date
- 4 Jul 2025
- Primary completion date
- 10 Nov 2025
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT07213076
What you commit to
- Study type: Observational
- Participants enrolled: 350
- From 4 Jul 2025 to the primary completion date, 10 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There are no predefined exclusion criteria.
Who the study is looking for
- Male or female, aged at least 18 years.
- Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy, patients with relapsed/recurrent disease and prior treatment in early-stage setting allowed.
- The tumour harbours an activating EGFR mutation
- Enrolled in the AURORA registry
- Patients must be either:
- treatment-naïve for advanced NSCLC (allowing up to 2-cycles of bridging chemotherapy prior to molecular testing results) and initiated 1L Osimertinib per PBS restrictions from August 2020 to December 2022.
- Previously treated with 1st or 2nd generation EGFR TKIs (gefitinib, erlotinib or afatinib) and confirmed T790M+ EGFRm at disease progression and initiated second-line Osimertinib per PBS restrictions from January 2016 to December 2022.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.